Cardiol Therapeutics Inc. (CRDL.TO) TSX

1.49

-0.05(-3.25%)

Updated at September 08 10:07AM

Currency In CAD

Cardiol Therapeutics Inc.

Address

2265 Upper Middle Road East

Oakville, ON L6H 0G5

Canada

Phone

289 910 0850

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

18

First IPO Date

December 20, 2018

Key Executives

NameTitlePayYear Born
Mr. David G. Elsley MBAPresident, Chief Executive Officer & Director787,500N/A
Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBAChief Financial Officer, Corporate Secretary & Director308,000N/A
Mr. Bernard Lim B.Sc.Chief Operating Officer539,000N/A
Dr. Andrew Warwick Hamer M.D.Chief Medical Officer and Head of Research & Development787,6131962
Mr. John A. Geddes BSCPT, MBAVice President of Corporate Development0N/A
Trevor BurnsInvestor Relations0N/A

Description

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.